Table 1 Demographic and clinico-pathologic features of all 121 SBA patients.

From: PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability

 

CeD-SBA

CrD-SBA

Sporadic

Overall

Post hoc comparison

SBA

p value

p value

Number

34

49

38

  

Age at SBA diagnosis

Median (25–75th IQR), yrs

53.5

(42.7–66)

58

(51–67.5)

69

(62–77)

<0.001

CeD vs CrD: 0.129

CeD vs sporadic: <0.001

CrD vs sporadic: <0.001

Duration of inflammatory disorder at SBA diagnosis

Median (25–75th IQR), mo

23.5

(12–110.25)

156

(6–288)

NA

0.016

 

Sex, N (%)

     

Female

Male

18 (53)

16 (47)

13 (27)

36 (73)

14 (37)

24 (63)

0.049

CeD vs CrD: 0.014

CeD vs sporadic: 0.169

CrD vs sporadic: 0.302

Site, N (%)*

     

Duodenum

Jejunum

Ileum

7 (21)

23 (70)

3 (9)

1 (2)

2 (4)

46 (94)

3 (8)

24 (63)

11 (29)

<0.001

CeD vs CrD: <0.001

CeD vs sporadic: 0.053

CrD vs sporadic: <0.001

Stage, N (%)**

     

I

II

III

IV

3 (9)

19 (60)

8 (25)

2 (6)

6 (12)

19 (39)

18 (37)

6 (12)

2 (5)

17 (46)

15 (41)

3 (8)

0.550

 

Histotype, N (%)

     

Glandular

Medullary

Diffuse

Mixed

Solid

19 (56)

6 (17)

2 (6)

4 (12)

3 (9)

24 (50)

2 (4)

10 (20)

12 (24)

1 (2)

22 (58)

1 (3)

2 (5)

10 (26)

3 (8)

0.032

CeD vs CrD: 0.032

CeD vs sporadic: 0.187

CrD vs sporadic: 0.228

CD3+ TILs/HPF

Median (25–75th IQR)

25.1

(12.3–75.4)

7.1

(2–20.6)

7.1

(2.2–20.9)

<0.001

CeD vs CrD: <0.001

CeD vs sporadic: <0.001

CrD vs sporadic: 0.962

MSI status, N (%)

     

Non-MSI

MSI-H

12 (35)

22 (65)

40 (82)

9 (18)

30 (79)

8 (21)

<0.001

CeD vs CrD: <0.001

CeD vs sporadic: <0.001

CrD vs sporadic: 0.754

CDX2 expression, N (%)***

     

Negative

Positive

5 (15)

28 (85)

22 (46)

26 (54)

11 (29)

27 (71)

0.012

CeD vs CrD: 0.003

CeD vs sporadic: 0.165

CrD vs sporadic: 0.109

L-FABP expression, N (%)****

     

Negative

Positive

30 (88)

4 (12)

39 (81)

9 (19)

17 (45)

21 (55)

<0.001

CeD vs CrD: 0.393

CeD vs sporadic: <0.001

CrD vs sporadic: <0.001

  1. CeD-SBA celiac disease-associated small bowel adenocarcinoma, CrD-SBA Crohn’s disease-associated small bowel adenocarcinoma, HPF high-power field, IQR interquartile range, L-FABP liver fatty acid-binding protein, mo month, MSI microsatellite instability, MSI-H microsatellite instability-high, NA not applicable, SBA small bowel adenocarcinoma, TIL tumor-infiltrating lymphocyte, yr year.
  2. *In one CeD-SBA, the precise tumor site within small bowel was unknown.
  3. **In two CeD-SBAs and in one sporadic SBA, the precise stage was unknown.
  4. ***In one CeD-SBA and in one CrD-SBA, no section for CDX2 immunohistochemistry was available.
  5. ****In one CrD-SBA, no section for L-FABP immunohistochemistry was available.
Back to article page